• Biohaven Reaches Targeted Therapeutic Exposures of BHV-3500 americanpharmaceuticalreview
    February 19, 2019
    Biohaven announced that administration of intranasal BHV-3500 in a Phase 1 clinical trial has achieved targeted therapeutic exposures and that the compound will advance into a Phase 2 trial to evaluate efficacy for the acute treatment of migraine....
  • Biohaven Announces Submission of IND for BHV-3500 americanpharmaceuticalreview
    September 13, 2018
    Biohaven has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the safety and tolerability of BHV-3500, the first small molecule calcitonin gene-related peptide (CGRP) receptor antagonist to
PharmaSources Customer Service